Cancer pulmonaire - Rôle des TLR7 et TLR8 dans la survie cellulaire et la résistance à la chimiothérapie

Julien Cherfils-Vicini; Diane Damotte; Wolf-Herman Fridman; Catherine Sautès-Fridman; Isabelle Cremer

doi:10.1051/medsci/2010264435

Accueil

Tous les numéros

Volume 26 / Numéro 4 (Avril 2010)

Med Sci (Paris), 26 4 (2010) 435-438

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 26, Numéro 4, Avril 2010


Page(s)		435 - 438
Section		Forum
DOI		https://doi.org/10.1051/medsci/2010264435
Publié en ligne		15 avril 2010

Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420 : 860–7. [Google Scholar]
Littman AJ, Thornquist MD, White E, et al. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004; 15 : 819–27. [Google Scholar]
Ardies CM. Inflammation as cause for scar cancers of the lung. Integr cancer ther 2003; 2 : 238–46. [Google Scholar]
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5 : 749–59. [Google Scholar]
Pikarsky E, Porat R, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431 : 461–466. [Google Scholar]
He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44 : 2850–9. [Google Scholar]
Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005; 6 : 1. [Google Scholar]
Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006; 16 : 32–7. [Google Scholar]
Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 8 mars : pli 36551. doi : 10.1172/JCI 36551. [Google Scholar]
Brevet Européen (demande déposée en août 2008): EP08305490. Methods for predicting the response to treatment and for treating cancer. Fridman WH, Cherfils-Vicini J, Cremer I. Extension PCT: PCT/EP2009/060555. [Google Scholar]
Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350 : 379–92. [Google Scholar]
Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26 : 4410–7. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420 : 860–7. [Google Scholar]

[2] Littman AJ, Thornquist MD, White E, et al. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004; 15 : 819–27. [Google Scholar]

[3] Ardies CM. Inflammation as cause for scar cancers of the lung. Integr cancer ther 2003; 2 : 238–46. [Google Scholar]

[4] Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5 : 749–59. [Google Scholar]

[5] Pikarsky E, Porat R, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431 : 461–466. [Google Scholar]

[6] He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44 : 2850–9. [Google Scholar]

[7] Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005; 6 : 1. [Google Scholar]

[8] Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006; 16 : 32–7. [Google Scholar]

[9] Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 8 mars : pli 36551. doi : 10.1172/JCI 36551. [Google Scholar]

[10] Brevet Européen (demande déposée en août 2008): EP08305490. Methods for predicting the response to treatment and for treating cancer. Fridman WH, Cherfils-Vicini J, Cremer I. Extension PCT: PCT/EP2009/060555. [Google Scholar]

[11] Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350 : 379–92. [Google Scholar]

[12] Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26 : 4410–7. [Google Scholar]